US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ASTRAZENECA PLC ADRhedged

53.28

0.0000

Volume:- -

Turnover:- -

Market Cap:1.60M

PE:- -

High:53.28

Open:53.28

Low:53.28

Close:53.28

52wk High:56.90

52wk Low:44.36

Shares:30.00K

Float Shares:10.00K

Volume Ratio:2.68

T/O Rate:- -

Dividend:0.58

Dividend Rate:1.08%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Stocks to Watch: CXMT, LVMH, Nvidia, Chevron

Astrazeneca's Ultomiris Misses Primary Goal in Late-Stage Rare-Disease Trial

MT Newswires Live

AstraZeneca Reports 'Positive' Phase 3 Results for Sonesitatug Vedotin in Claudin 18.2-Positive Gastric Cancers

MT Newswires Live

AstraZeneca Q2 Core Earnings, Revenue Rise

MT Newswires Live

AstraZeneca Results Should Allay Investor Fears

AstraZeneca Beats Q2 Earnings Estimates, Focus Shifts to Next-Generation Oncology Drug Pipeline

AstraZeneca Q2 Adj. EPS $2.63 Beats $2.48 Estimate, Sales $15.384B Miss $15.459B Estimate

Benzinga Earnings

Astrazeneca Q2 Revenue Rises 6% on Demand for Its Cancer Therapies

Astrazeneca PLC Stock Rises Friday, Underperforms Market

Astrazeneca's Drug Pipeline in Focus After Recent Trial Miss

AstraZeneca, Daiichi Sankyo's Enhertu Combination Therapy Recommended for EU Approval in Breast Cancer

MT Newswires Live

AstraZeneca's Trixeo Recommended for EU Approval to Treat Asthma

MT Newswires Live

AstraZeneca, Daiichi’s Enhertu with pertuzumab recommended for approval in EU

AstraZeneca announces Trixeo Aerosphere recommended for approval in EU

Astrazeneca PLC Expected to Post Earnings of $2.54 a Share - Earnings Preview

AstraZeneca announces Etcamah with CDK4/6 inhibitor approved in EU

Astrazeneca's Etcamah combination for ESR1-mutated advanced breast cancer

MT Newswires Live

European Union Grants Approval to AstraZeneca's New Breast Cancer Medication

Astrazeneca PLC Stock Rises Wednesday, Outperforms Market

What Bundibugyo Ebola Vaccines and Treatments are Under Development

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/AZNH/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AZNH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","market":"US","secType":"STK","nameCN":"ASTRAZENECA PLC ADRhedged","latestPrice":53.2774,"timestamp":1787342400000,"preClose":53.2774,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":10000,"shares":30000,"eps":0,"marketStatus":"Halted","change":0,"latestTime":"08-21 16:00:00 EDT","open":53.2774,"high":53.2774,"low":53.2774,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":53.2774,"dividendRate":0.010836,"bidAskSpread":0,"volumeRatio":2.6812474453400963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","floatShares":10000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.6812474453400963,"shares":30000,"dividePrice":0.57729,"high":53.2774,"amplitude":0,"preClose":53.2774,"low":53.2774,"week52Low":44.36,"pbRate":"--","week52High":56.8955,"institutionHeld":0,"latestPrice":53.2774,"eps":0,"divideRate":0.010836,"volume":0,"delay":0,"ttmEps":0,"open":53.2774,"prevYearClose":54.226,"prevWeekClose":53.2774,"prevMonthClose":53.2774,"prevQuarterClose":53.2774,"fiveDayClose":53.2774,"twentyDayClose":53.2774,"sixtyDayClose":53.2774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AZNH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"AZNH","amount":0.57729,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2024-12-16","symbol":"AZNH","amount":2.71402,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AZNH\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-16","recordDate":"2024-12-16","paymentDate":"2024-12-23","value":2.71402,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.57729,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AZNH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AZNH\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654015540","title":"Stocks to Watch: CXMT, LVMH, Nvidia, Chevron","url":"https://stock-news.laohu8.com/highlight/detail?id=2654015540","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654015540?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:05","pubTimestamp":1785143100,"startTime":"0","endTime":"0","summary":"Nvidia (NVDA): The AI chip company is in talks to provide a $250 billion backstop to OpenAI to fund a massive data-center project, WSJ reported. Shares ticked up in premarket trading along with other ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","LU1066053197.SGD","LU0708994859.HKD","NVDS.UK","VGT","LU0788109477.HKD","WEEI","LU1267930490.SGD","LU2125909916.SGD","LU0889565833.HKD","AIFD","LU1732800096.USD","AGOX","LU0612318971.USD","LU0545039389.USD","LU0354030511.USD","LU1035773651.USD","BK4550","LU2294711713.HKD","LU1935042991.SGD","LU0553294199.USD","LU0056508442.USD","LU0345770993.USD","LU0210536198.USD","ARTY","LU0106261372.USD","LU2458330243.SGD","CMAG","IE0004086264.USD","LU2471134796.USD","LU2360032135.SGD","LU2458330169.SGD","LU1633808545.USD","LU2129689514.USD","SG9999014914.USD","LU1430594728.SGD","BK4529","LU1863844665.USD","LFGY","IE00BFSS8Q28.SGD","LU1983260115.SGD","LU1150488218.USD","LU0072462426.USD","LU0345781412.USD","LU2023251221.USD","LU0965509010.AUD","LU1280957306.USD","LU1935043023.USD","LU1430597077.USD","LU1814569148.SGD","IE00B19Z9505.USD","LU1242518931.SGD","BK4554","LU1935043536.SGD","NVDW","LU1642822529.SGD","LU2602419157.SGD","SG9999015978.USD","SG9999001440.SGD","LU0238689110.USD","LU0943347566.SGD","BK4202","LU0345768740.USD","JGRO","LU1880398554.USD","LU1720051108.HKD","LU2491050154.USD","LU2361045086.USD","688825","LU2471134952.CNY","LU2264538146.SGD","LU0070217475.USD","LU0058720904.USD","HK0000304805.HKD","LU1116320901.HKD","SG9999015952.SGD","LU0187121727.USD","LU2552382215.SGD","FAI","IE00BQXX3D17.EUR","LU0795875169.SGD","LU0256863902.USD","CHPX","LU2860962120.EUR","LU0289961442.SGD","LU0175139822.USD","LU0792757196.USD","CVX","LU0466842654.USD","LU1951198990.SGD","LU0347712357.USD","LU0122376428.USD","BK4568","2NVD.UK","LU0057025933.USD","LU2065171311.SGD","IE0034235303.USD","LU2237443622.USD","XOMZ","LU1316542783.SGD","LU1721428933.USD","LU2168564495.EUR","LU0820561909.HKD","BK4581","LU0266512127.USD","LU2125909593.SGD","SGXZ99366536.SGD","LU2272731865.HKD","LU2420271590.USD","LU1917777945.USD","BK4503","LU0823421416.USD","LU2357305700.SGD","CNEQ","LU0323239441.USD","LU0300736062.USD","LU2506951792.HKD","LU0859254822.USD","LU2249611893.SGD","LU1992135399.USD","LU2125154778.USD","SGXZ31699556.SGD","LU1429558221.USD","LU0557290698.USD","NVD2.UK","LU1066051811.HKD","LU0109394709.USD","IE000Q6AESB8.SGD","LU1037948897.HKD","LU2463028550.USD","BK4543","LU1868836757.USD","LU1489326972.SGD","LU1496350171.SGD","SG9999014575.USD","LU0109392836.USD","LU0094547139.USD","LU0456854461.SGD","IE0005OL40V9.USD","LU2498475776.HKD","NVYY","BK4566","LU2746668974.SGD","LU0985320562.USD","IE000ITXATA3.USD","LU0689472784.USD","LU2272731782.SGD","LU1880398471.USD","LU1914381329.SGD","IE00B19Z3581.USD","LU0432979614.USD","WISE","LU2491050071.SGD","IE00BK4W5M84.HKD","TRUN","LU0316494557.USD","LU1852331112.SGD","LU0642271901.SGD","LU2242649171.HKD","IE00BKPKM429.USD","LU2237443382.USD","BK4598","LU2543165471.USD","SNVD.UK","LU0786609619.USD","HK0000914686.HKD","IE00BZ199S13.USD","LU2750360997.AUD","IE00B19Z8W00.USD","LU2487616109.SGD","LU2168564222.USD","LU1435385759.SGD","LU1496350502.SGD","LU2999663052.SGD","ESUM","LU0133085943.USD","LU0787776722.HKD","LU1267930573.SGD","HK0000320223.HKD","LU2054465674.USD","LU0170899867.USD","BK4614","LU2756315318.SGD","IE00B1BXHZ80.USD","LU2102340556.USD","XLK","LU0210533765.USD","IE000YTNTUN2.SGD","LU2100268510.USD","IE0034235188.USD","TTXU","LU1923623000.USD","IYE","LU0957808578.USD","HK0000532082.HKD","IE00BKDWB100.SGD","LU1244550494.USD","LU1894683348.USD","LU2111349929.HKD","LU1571399168.USD","LU2430703251.USD","LU0029864427.USD","LU0096362180.USD","NVDX","LU1934455194.USD","LU0823421333.USD","LU2347655156.SGD","LU0708995401.HKD","GB00BDT5M118.USD","LU1923622291.USD","LU0310800379.SGD","LU2237438978.USD","IE00BGHQF524.EUR","LU0266013472.USD","NVD","HK0000320264.USD","LU0109391861.USD","LU2290526834.HKD","TEK","LU1645745479.HKD","LU2237957811.SGD","IE0002270589.USD","LU1629891620.HKD","LU2125154935.USD","XOM","LU0640476718.USD","LU0345768153.USD","IE000M9KFDE8.USD","LU0158827781.USD","LU0345770308.USD","LU1084165304.USD","LU1732799900.SGD","LU2403377893.USD","IE00BJTD4V19.USD","XOMX","IE00BJJMRX11.SGD","LU2413666699.HKD","LU2236285917.USD","DIPS","LU2129689605.HKD","LU2272731600.USD","SG9999014898.SGD","LU0107464264.USD","LU2452424414.USD","LU0128525929.USD","LU2279689827.SGD","07788","GXPE","LU2360106780.USD","LU2065171402.SGD","LU0433182093.SGD","IGE","LU0868494617.USD","BK4587","CHAT","LU0738911758.USD","LU1585245621.USD","LU2211815571.USD","LU1989764748.USD","LU0323591593.USD","LU1400636657.SGD","LU2552382132.HKD","LU2322448957.HKD","LU2592432038.USD","LU1868837136.USD","LU1974910355.USD","LU1037948541.HKD","LU0143551892.USD","LU2361044865.SGD","LU2023250330.USD","LU0203345920.USD","LU2637965513.SGD","LU2265009873.SGD","LU0724617625.USD","LU2106854487.HKD","LU2471134879.HKD","LU2756315664.SGD","BK4579","IE00BZ1G4Q59.USD","LU0719512351.SGD","ANV","LU0124676726.USD","LU0098860793.USD","LU0158827948.USD","LU2552382058.USD","SGXZ51526630.SGD","LU0070302665.USD","LU2065170008.USD","LU1074936037.SGD","NVDG","SG9999017495.SGD","SG9999002521.SGD","LU1803068979.SGD","LU1923622614.USD","IE00BJJMRY28.SGD","LU1244550221.USD","LU1032466523.USD","LU0289739699.SGD","LU0345780950.USD","LU0006306889.USD","LU0820561818.USD","IE00B3SWFQ91.USD","LU0494093205.USD","LU0157215616.USD","LU1992135472.HKD","LU0061475181.USD","LU0882574139.USD","HK0000306701.USD","LU0476273544.USD","LU0011850046.USD","LU2247934214.USD","IE0004445015.USD","LU2417539215.USD","LU2089284900.SGD","LU1934455863.HKD","SG9999014542.SGD","LU1232071149.USD","BK4567","BK4534","LU2271345857.HKD","LU2092937148.SGD","LU2097344357.USD","LU2092627202.USD","LU1582986433.USD","IE0001KFT4U8.USD","LU0289739343.SGD","IE00BFXG1179.USD","LU1323610961.USD","LU0823434740.USD","LU1582986359.USD","LU2954938101.SGD","BK4201","LU0251132253.USD","LU1951200564.SGD","SG9999015358.SGD","LU1989772923.USD","LU2244417387.USD","LU0053666078.USD","LU0323240290.USD","LU0868494708.USD","LU2250418816.HKD","IE00BN29S564.USD","IE00BD6J9T35.USD","LU2089283258.USD","TRFK","LU2381873111.SGD","IE00B3M56506.USD","LU2168564149.EUR","IE00B4YYXB79.USD","LU1267930813.SGD","LU0127658192.USD","LU1894683264.USD","BK4608","IE0004091025.USD","LU0942090050.USD","LU0069063385.USD","07388","LU1674673691.USD","LU1670756490.USD","LU2237443895.HKD","LU2242650005.HKD","LU1868836914.USD","LU1116320737.USD","LU1551013425.SGD","LU1929549753.HKD","LU0823414551.USD","LU1674673428.USD","SG9999015986.USD","LU1202635105.USD","IE00BHPRN162.USD","SG9999014906.USD","IE00BYXW3230.USD","NVDQ","LU1150488135.SGD","IE00BMPRXN33.USD","LU0965509283.SGD","LU0353189763.USD","LU0080751232.USD","BK4588","LU1839511570.USD","LU1366333091.USD","TTEQ","EFIV","LU0048584097.USD","LU2931357623.SGD","LU0203347892.USD","LU2746668461.USD","LU2023250504.SGD","METV","LU0965508806.USD","IE00B19Z8X17.USD","LU0354030438.USD","IE0009G5SDU7.USD","LU0965509101.SGD","LU0225283273.USD","LU1242518857.USD","LU2087625088.SGD","LU0395794307.EUR","LU0348723411.USD","HK0000914660.USD","LU1261432733.SGD","LU1244550577.SGD","LU2108987350.USD","LU0320765646.SGD","LU0889566641.SGD","LU2394011477.USD","LU0138981039.USD","LU0234570918.USD","LU0274383776.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","IE00BJLML261.HKD","LU3102509885.SGD","IE000KEQY171.SGD","3NVD.UK","LU1551013342.USD","SG9999018865.SGD","IE0009356076.USD","SG9999018857.SGD","LU0353189680.USD","LU2357125470.USD","LU0210528500.USD","LU1582987597.SGD","LU0985489474.SGD","FENY","LU1863844749.USD","BK4570","NVII","LU1720051017.SGD","LU2473716301.USD","LU1989772840.SGD","LU1066051225.USD","GAMR","LU2430703178.SGD","LU1861215975.USD","LU0612318385.USD","LU2237957902.USD","NVDD","IXN","LU0154236417.USD","LU2237443978.SGD","LU2896262040.SGD","LU1267930730.SGD","LU1691799644.USD","LU1582987324.SGD","IE0034235295.USD","LU1366192091.USD","IE00B775SV38.USD","LU1162221912.USD","IE00BDRTCR15.USD","LU0096364046.USD","SGXZ81514606.USD","TYLG","NVIW.SI","LU1988902786.USD","SG9999015945.SGD","SG9999014559.SGD","LU0672654240.SGD","LU1127390331.HKD","IE0004445239.USD","LU0345769631.USD","LU0211328371.USD","LU0265550946.USD","SG9999004303.SGD","NVDO","LU0203201768.USD","VT","ILDR","LU2237443465.HKD","IE00BMPRXQ63.HKD","SG9999002224.SGD","LU2213496289.HKD","SPTE","LU0276348264.USD","LU2462591350.SGD","FTEC","LU0878866978.SGD","SG9999014567.USD","LU2505996509.AUD","CLSE","LU1069344957.HKD","LU2413666426.HKD","NULC","IE00BQXX3C00.GBP","LU2462157665.USD","SG9999015341.SGD","TEXU","LU0320765059.SGD","IE00BFSS7M15.SGD","LU0912757837.SGD","LU0198837287.USD","LU2361044949.HKD","AZN","LU1815336760.USD","LU2430703095.HKD","LU2237443549.SGD","LU2347655073.USD","LU0823414478.USD","IE00BK4W5L77.USD","LU0081259029.USD","BK4612","LU0097036916.USD","LU0211327993.USD","LU1712237335.SGD","LU0654597011.USD","LU1868837300.USD","LU0310799852.SGD","LU2491049909.HKD","IE00BQXX3F31.USD","LU1791710400.SGD","LU0795875086.SGD","IE00B3T34201.USD","LU0823434583.USD","LU1064131342.USD","LU0661504455.SGD","LU1035775433.USD","LU2168563687.JPY","LU2461242641.AUD","LU0342679015.USD","LVMHF","LU0082616367.USD","LU2125909759.SGD","IE00B7KXQ091.USD","LU1145028129.USD","IE00B2Q91V27.USD","LU0949170772.SGD","SHOC","LU1935042215.USD","LU0234572021.USD","LU2168564065.EUR","LU2286300806.USD","LU1400636574.HKD","LU1804176565.USD","LU1066051498.USD","SGXZ23171101.USD","LU0256863811.USD","LU1815333072.USD","IE00B5949003.HKD","LU1829250122.USD","LU1548497426.USD","LU0957791311.USD","LU0320765489.SGD","BK4551","LU0417517546.SGD","IE00B3CCJ963.GBP","LU0726765562.USD","LU0368265418.SGD","LU0689626769.HKD","AZNH","IE00B1XK9C88.USD","SNPE","LU0788109394.HKD","ABFL","ROM","LU2357627491.SGD","NVDS","LU1821325948.USD","LU0630314457.HKD","LU0208291251.USD","LU2089984988.USD","LU0289960550.SGD","LU0390134368.USD","LU2471134523.USD","LU1153585028.USD","LU0345769128.USD","LU0979878070.USD","LU2191332357.HKD","LU1989764664.SGD","IE000W1ABFV2.USD","LU2129689431.USD","LU2433249047.HKD","SG9999001424.SGD","BK4592","HK0000819398.USD","LU1400636491.USD","LU2456880835.USD","LU2148611432.USD","LU0278409577.USD","NVDL","SG9999000418.SGD","BK4549","BK4516","LU0889565916.HKD","SG9999014880.SGD","LU0266512473.USD","LU0472753341.HKD","BK4527","LU0265550359.USD","LU0061474960.USD","LU0174119429.USD","THMR","LU1935042488.USD","LU0149725797.USD","LU0444973449.USD","LU1778281490.HKD","LU0528227936.USD","IE00BKVL7J92.USD","IE0003U64NQ7.SGD","LU1791710582.SGD","LU2077746001.SGD","NVDU","LU2505996681.GBP","LU1003077747.HKD","LU2326559502.SGD","LU0320765992.SGD","LU0683600562.USD","IE00BMPRXR70.SGD","BK4559","LU0964807845.USD","LU2028103732.USD","LU3187612489.SGD","LU0215105999.USD","LU0061474705.USD","LU1861220033.SGD","HK0000304797.USD","USXF","LU1718418525.SGD","LU2087621335.USD","LU2097344431.USD","LU2462591277.SGD","BK4585","LU0203202063.USD","LU0444971666.USD","LU1069347547.HKD","IETC","IE00BWXC8680.SGD","LU2063271972.USD","LU0256331488.USD","LU2047632596.USD","LU1623119135.USD","LU2360107168.USD","AIPI","LU0861579265.USD","IE00B4JS1V06.HKD","NVD3.UK","LU2133065610.SGD","BK4532","LU0077335932.USD","LU2750360641.GBP","LU0300736492.USD","LU2065169927.USD","SG9999002232.USD","LU2125909247.SGD","LU0068578508.USD","NVDA","LU2322448791.USD","LU2462611646.USD","HK0000306685.HKD","LU0308772762.SGD","BK4548","LU1119994496.HKD","IE00B775H168.HKD","BK4605","BK4007","BK4533","LU1861127337.USD","NVDY","IE00B3S45H60.SGD","LU1868836591.USD","LU0267386448.USD","LU0511384066.AUD","IE00B19Z3B42.SGD","FDTX","BK4141","LU0079474960.USD","XOMO","ESLG","IE00BJTD4N35.SGD","LU0820562030.AUD","LU1934455277.USD","LU1883866441.USD","IE00BDCRKT87.USD","LU2089985449.USD","NVDB","LU2083900584.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654015377","title":"Astrazeneca's Ultomiris Misses Primary Goal in Late-Stage Rare-Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654015377","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654015377?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:05","pubTimestamp":1785143100,"startTime":"0","endTime":"0","summary":"Astrazeneca's  Ultomiris missed the primary endpoint in a phase 3 trial in patients with thrombotic microangiopathy after stem-cell transplant, the company said Monday.The therapy failed to achieve statistical significance for event-free survival at 26 weeks in adult and adolescent patients, though the study showed a trend toward benefit versus placebo, the company said.Astrazeneca said discussions with regulators are ongoing regarding interpretation of the data.In a separate phase 3 trial in pediatric patients, Ultomiris delivered clinically meaningful overall survival of 87.2% at 26 weeks at 73.4% at 52 weeks, and the company said it will advance regulatory filings for use in children.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2468319806.SGD","BK4585","LU0029864427.USD","AZNH","IE00B3T34201.USD","LU2237443622.USD","LU0128525929.USD","LU2456880835.USD","LU0058720904.USD","AZN","LU2237443382.USD","LU2417539215.USD","LU0889565916.HKD","LU2237443978.SGD","LU0432979614.USD","LU1829250122.USD","LU2237443465.HKD","LU2089984988.USD","LU2462157665.USD","LU2237443549.SGD","BK4588","LU1267930573.SGD","LU0289739699.SGD","LU0109394709.USD","LU2236285917.USD","LU2237443895.HKD","BK4007","BK4568","LU0708994859.HKD","LU0310800379.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654013427","title":"AstraZeneca Reports 'Positive' Phase 3 Results for Sonesitatug Vedotin in Claudin 18.2-Positive Gastric Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2654013427","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654013427?lang=en_us&edition=fundamental","pubTime":"2026-07-27 16:53","pubTimestamp":1785142381,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) said Monday that its Phase 3 CLARITY-Gastric01 trial met the dual primary overall survival endpoint for sonesitatug vedotin in patients with Claudin 18.2-positive advanced gastric, g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443465.HKD","LU2237443895.HKD","LU0320765992.SGD","IE00B3T34201.USD","LU0310800379.SGD","LU2237443549.SGD","LU2456880835.USD","BK4007","LU0889565916.HKD","LU0128525929.USD","LU2468319806.SGD","BK4568","AZN","LU2237443622.USD","LU0432979614.USD","LU2237443382.USD","LU0029864427.USD","LU2236285917.USD","BK4588","BK4585","LU2237443978.SGD","LU1267930573.SGD","LU2089984988.USD","LU2462157665.USD","LU0708994859.HKD","LU0289739699.SGD","AZNH","LU0058720904.USD","LU2417539215.USD","LU1829250122.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654906620","title":"AstraZeneca Q2 Core Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2654906620","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654906620?lang=en_us&edition=fundamental","pubTime":"2026-07-27 15:39","pubTimestamp":1785137972,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) reported Q2 core earnings Monday of $2.63 per diluted share, up from $2.17 a year earlier.Analyst polled by FactSet expected $2.49.Revenue for the quarter ended June 30 was $15.38 bi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443465.HKD","LU2237443895.HKD","AZN","LU0058720904.USD","LU2089984988.USD","BK4585","LU2462157665.USD","BK4568","LU0109394709.USD","IE00B3T34201.USD","LU2237443622.USD","LU2237443978.SGD","LU2236285917.USD","LU1267930573.SGD","LU0320765992.SGD","LU0029864427.USD","LU2468319806.SGD","BK4007","BK4588","LU0708994859.HKD","LU0889565916.HKD","LU0128525929.USD","LU2237443382.USD","LU2417539215.USD","LU0310800379.SGD","LU2456880835.USD","LU2237443549.SGD","LU0289739699.SGD","LU0432979614.USD","AZNH","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654097205","title":"AstraZeneca Results Should Allay Investor Fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2654097205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654097205?lang=en_us&edition=fundamental","pubTime":"2026-07-27 15:13","pubTimestamp":1785136380,"startTime":"0","endTime":"0","summary":"0713 GMT - AstraZeneca's solid results should allay investor fears about the U.K. drugmaker's long-term targets, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. The company reiterated its guidance for this year and its 2030 target despite the failure of a clinical trial for its Wainua drug earlier this month, the analysts say. AstraZeneca also said experimental treatment sonesitatug vedotin showed positive overall-survival results--but not on survival without the disease getting worse--in a late-stage study for gastric cancers, which should contribute to ease some fears about its pipeline strength and ability to innovate, they add. Shares rise 1%.  Dow Jones NewswiresJuly 27, 2026 03:13 ET Copyright  2026 Dow Jones & Company, Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","BK4588","LU2236285917.USD","LU0708994859.HKD","LU1829250122.USD","LU0128525929.USD","LU1267930573.SGD","LU2417539215.USD","LU2237443978.SGD","LU0432979614.USD","LU0310800379.SGD","LU0058720904.USD","LU0889565916.HKD","LU0029864427.USD","LU0289739699.SGD","AZNH","LU2456880835.USD","LU2089984988.USD","BK4007","IE00B3T34201.USD","LU0109394709.USD","LU2237443622.USD","LU2468319806.SGD","LU2462157665.USD","LU2237443382.USD","LU0320765992.SGD","LU2237443465.HKD","LU2237443549.SGD","BK4585","LU2237443895.HKD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113109570","title":"AstraZeneca Beats Q2 Earnings Estimates, Focus Shifts to Next-Generation Oncology Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1113109570","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113109570?lang=en_us&edition=fundamental","pubTime":"2026-07-27 15:06","pubTimestamp":1785135976,"startTime":"0","endTime":"0","summary":"AstraZeneca PLC (NASDAQ: AZN) reported second-quarter earnings that surpassed expectations, driven by strong sales of its blockbuster cancer drugs. The market's attention is now turning to the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZECP","LU0058720904.USD","BK4568","AZNH","LU2462157665.USD","BK4588","LU1267930573.SGD","BK4007","LU0128525929.USD","LU0109394709.USD","LU2468319806.SGD","LU2089984988.USD","LU0889565916.HKD","LU2237443622.USD","LU0708994859.HKD","LU0320765992.SGD","LU2417539215.USD","AZN","LU2237443895.HKD","LU0310800379.SGD","LU1829250122.USD","BK4585","LU2237443465.HKD","LU2236285917.USD","LU2237443549.SGD","LU2237443978.SGD","IE00B3T34201.USD","LU0029864427.USD","LU2456880835.USD","LU2237443382.USD","LU0289739699.SGD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654092071","title":"AstraZeneca Q2 Adj. EPS $2.63 Beats $2.48 Estimate, Sales $15.384B Miss $15.459B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2654092071","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654092071?lang=en_us&edition=fundamental","pubTime":"2026-07-27 14:52","pubTimestamp":1785135166,"startTime":"0","endTime":"0","summary":"AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $2.63 per share which beat the analyst consensus estimate of $2.48 by 6.05 percent. This is a 141.28 percent increase over earnings of $1.08 per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60687695/astrazeneca-q2-adj-eps-2-63-beats-2-48-estimate-sales-15-384b-miss-15-459b-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708994859.HKD","LU2237443465.HKD","LU2089984988.USD","BK4007","IE00B3T34201.USD","LU0058720904.USD","LU0310800379.SGD","LU2462157665.USD","LU1829250122.USD","BK4588","LU2237443549.SGD","AZN","LU2237443978.SGD","LU0109394709.USD","LU2237443895.HKD","LU2417539215.USD","BK4585","LU2456880835.USD","LU2468319806.SGD","LU0289739699.SGD","LU2237443622.USD","LU0889565916.HKD","LU0029864427.USD","LU2237443382.USD","LU1267930573.SGD","BK4568","LU0128525929.USD","LU0432979614.USD","LU2236285917.USD","AZNH","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654094708","title":"Astrazeneca Q2 Revenue Rises 6% on Demand for Its Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2654094708","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654094708?lang=en_us&edition=fundamental","pubTime":"2026-07-27 14:14","pubTimestamp":1785132850,"startTime":"0","endTime":"0","summary":"AstraZeneca Q2 revenue rises 6% on demand for its cancer therapiesOverviewUK pharma firm's Q2 revenue rose 6% yr/yr, slightly missing analyst expectationsCore EPS for Q2 rose 21% and beat analyst expe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d54d6b0526504b5280857fea1664cacb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL1N43T05Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU2237443895.HKD","AZN","LU0058720904.USD","LU2089984988.USD","BK4585","LU2462157665.USD","BK4568","LU0109394709.USD","IE00B3T34201.USD","LU2237443622.USD","LU2237443978.SGD","LU2236285917.USD","LU1267930573.SGD","LU0320765992.SGD","LU0029864427.USD","LU2468319806.SGD","BK4007","BK4588","LU0708994859.HKD","LU0889565916.HKD","LU0128525929.USD","LU2237443382.USD","LU2417539215.USD","LU0310800379.SGD","LU2456880835.USD","LU2237443549.SGD","LU0289739699.SGD","LU0432979614.USD","AZNH","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654803682","title":"Astrazeneca PLC Stock Rises Friday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2654803682","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654803682?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:00","pubTimestamp":1784908800,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of AstraZeneca PLC rose 0.1% to SEK1,650.00 Friday on what proved to be an overall positive trading session for the stock market, with the OMX Nordic 40 Index rising 0.7% to 2,671.32.The company closed SEK275.50 short of its 52-week high of SEK1,925.50, which the company reached on April 10, 2026.Trading volume was 223,339, compared to the 50-day average trading volume of 322,079.Data source: Dow Jones Market Data, FactSet Dow Jones NewswiresJuly 24, 2026 12:00 ET Copyright  2026 Dow Jones & Company, Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930573.SGD","LU0109394709.USD","BK4007","LU2089984988.USD","LU2237443382.USD","IE00B3T34201.USD","LU0289739699.SGD","LU0889565916.HKD","LU2236285917.USD","LU2237443465.HKD","LU0029864427.USD","LU0708994859.HKD","BK4568","LU2462157665.USD","LU0432979614.USD","LU2237443978.SGD","LU0310800379.SGD","LU2237443622.USD","LU2237443895.HKD","LU2417539215.USD","LU2237443549.SGD","AZNH","LU0058720904.USD","LU0128525929.USD","LU2456880835.USD","LU0320765992.SGD","LU1829250122.USD","BK4585","AZN","LU2468319806.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653084950","title":"Astrazeneca's Drug Pipeline in Focus After Recent Trial Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2653084950","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653084950?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:03","pubTimestamp":1784894580,"startTime":"0","endTime":"0","summary":"AstraZeneca is scheduled to report results for the second quarter on Monday. Here is what you need to know.REVENUE FORECAST: The U.K. drugmaker is expected to report total revenue of $15.42 billion fo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Astrazeneca's Drug Pipeline in Focus After Recent Trial Miss","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4568","LU0128525929.USD","IE00B3T34201.USD","LU2237443978.SGD","LU2462157665.USD","LU2468319806.SGD","LU0310800379.SGD","LU2417539215.USD","LU1267930573.SGD","AZN","LU0058720904.USD","LU2237443895.HKD","LU0289739699.SGD","LU2236285917.USD","LU2456880835.USD","LU2237443622.USD","LU0708994859.HKD","LU2089984988.USD","LU2237443465.HKD","LU2237443549.SGD","BK4007","LU1829250122.USD","LU0029864427.USD","LU0109394709.USD","AZNH","LU2237443382.USD","LU0432979614.USD","LU0320765992.SGD","LU0889565916.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653708149","title":"AstraZeneca, Daiichi Sankyo's Enhertu Combination Therapy Recommended for EU Approval in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653708149","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653708149?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:42","pubTimestamp":1784893364,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Daiichi Sankyo's Enhertu, in combination with pertuzumab, was recommended for approval in the European Union as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, according to a Friday statement.The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval based on the results of a phase 3 trial, in which the combination therapy reduced the risk of disease progression or death by 44% versus taxane, trastuzumab and pertuzumab  treatment, Daiichi Sankyo said.The European Commission will now review the recommendation, the company added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU2417539215.USD","LU2237443465.HKD","LU0432979614.USD","LU0889565916.HKD","IE00B3T34201.USD","LU2089984988.USD","AZNH","LU2237443549.SGD","LU0128525929.USD","LU2237443382.USD","LU1829250122.USD","LU2236285917.USD","LU0320765992.SGD","LU0289739699.SGD","EPV","LU2462157665.USD","LU2237443978.SGD","LU2468319806.SGD","BK4568","AZN","LU1267930573.SGD","LU0708994859.HKD","LU2456880835.USD","BK4585","LU0109394709.USD","BK4156","BK4588","LU2237443622.USD","LU0310800379.SGD","LU2237443895.HKD","LU0058720904.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653081494","title":"AstraZeneca's Trixeo Recommended for EU Approval to Treat Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2653081494","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653081494?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:41","pubTimestamp":1784893312,"startTime":"0","endTime":"0","summary":"AstraZeneca  said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Trixeo Aerosphere as a maintenance treatment for asthma patients aged 12 and older who remain uncontrolled on medium-dose inhaled corticosteroid and long-acting beta2-agonist therapy.The positive opinion was based on Phase 3 KALOS and LOGOS trials, where Trixeo improved lung function and significantly reduced severe asthma exacerbations versus dual inhaled therapy in a pooled analysis.If approved by the European Commission, asthma would become the second indication for Trixeo in Europe, where it is already approved for the treatment of chronic obstructive pulmonary disease, it added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1829250122.USD","BK4588","LU1267930573.SGD","LU2089984988.USD","LU2468319806.SGD","LU0708994859.HKD","LU0128525929.USD","AZNH","LU0320765992.SGD","LU2237443622.USD","LU0289739699.SGD","AZN","LU2462157665.USD","LU2237443465.HKD","LU2237443895.HKD","LU2237443978.SGD","IE00B3T34201.USD","BK4568","LU2237443549.SGD","BK4585","BK4156","LU2417539215.USD","LU0889565916.HKD","LU0029864427.USD","BK4007","LU0058720904.USD","LU2237443382.USD","LU2456880835.USD","LU0310800379.SGD","LU0432979614.USD","LU0109394709.USD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653081154","title":"AstraZeneca, Daiichi’s Enhertu with pertuzumab recommended for approval in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2653081154","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653081154?lang=en_us&edition=fundamental","pubTime":"2026-07-24 19:30","pubTimestamp":1784892613,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu in combination with pertuzumab has been recommended for approval in the European Union, EU, for the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-daiichis-enhertu-with-pertuzumab-recommended-for-approval-in-eu-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-daiichis-enhertu-with-pertuzumab-recommended-for-approval-in-eu-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443465.HKD","LU2236285917.USD","LU0320765992.SGD","LU2456880835.USD","LU1267930573.SGD","BK4156","LU2417539215.USD","LU2237443895.HKD","LU0058720904.USD","LU2237443549.SGD","LU2237443382.USD","IE00B3T34201.USD","LU1829250122.USD","LU2468319806.SGD","BK4585","AZN","LU2462157665.USD","BK4588","EPV","LU0289739699.SGD","LU0889565916.HKD","LU0128525929.USD","LU0432979614.USD","LU0029864427.USD","BK4007","BK4568","LU2089984988.USD","LU0708994859.HKD","LU2237443978.SGD","LU2237443622.USD","AZNH","LU0109394709.USD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653808934","title":"AstraZeneca announces Trixeo Aerosphere recommended for approval in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2653808934","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653808934?lang=en_us&edition=fundamental","pubTime":"2026-07-24 18:51","pubTimestamp":1784890262,"startTime":"0","endTime":"0","summary":"AstraZeneca’s (AZN) fixed-dose triple-combination Trixeo Aerosphere has been recommended for approval in the European Union, EU, for the maintenanc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-trixeo-aerosphere-recommended-for-approval-in-eu-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-trixeo-aerosphere-recommended-for-approval-in-eu-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443465.HKD","LU2237443895.HKD","IE00B3T34201.USD","LU2237443549.SGD","BK4568","LU2237443382.USD","LU1267930573.SGD","LU2236285917.USD","LU2237443978.SGD","LU2468319806.SGD","AZNH","LU2417539215.USD","LU0320765992.SGD","LU2089984988.USD","LU0058720904.USD","BK4156","BK4007","LU0109394709.USD","LU2456880835.USD","LU0708994859.HKD","LU0029864427.USD","AZN","LU2462157665.USD","LU0128525929.USD","LU0289739699.SGD","LU0889565916.HKD","LU0432979614.USD","LU0310800379.SGD","BK4585","BK4588","LU2237443622.USD","EPV","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653304709","title":"Astrazeneca PLC Expected to Post Earnings of $2.54 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2653304709","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653304709?lang=en_us&edition=fundamental","pubTime":"2026-07-24 14:05","pubTimestamp":1784873124,"startTime":"0","endTime":"0","summary":"AstraZeneca PLCexpected to post earnings of $2.54 a share - Earnings PreviewAstraZeneca PLCAZN.Lis expected to  report resultson July 27 for the period ending June 30 2026The Cambridge United Kingdom-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL8N43Q091:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1084165304.USD","LU2357627491.SGD","LU0960981461.USD","LU2293690249.USD","LU0390134368.USD","LU0114720955.EUR","LU0949170772.SGD","LU0972486137.USD","LU1923622614.USD","LU0266013472.USD","LU1061106388.HKD","LU1273509221.SGD","LU1496350502.SGD","LU2125909247.SGD","LU0784385840.USD","LU1481600234.SGD","SGXZ57979304.SGD","IE00B2B36J28.USD","LU0553294199.USD","LU1496350171.SGD","LU0289739699.SGD","AZN","LU0889566641.SGD","LU0345777659.USD","LU0203347892.USD","AZN.UK","LU1015430645.USD","LU0920840948.USD","LU1057294990.SGD","LU0757432116.USD","LU0857590862.USD","LU1003077747.HKD","LU1051770623.HKD","03165","LU1196032939.SGD","LU0047473722.SGD","LU0158827948.USD","AZNH","LU0784384876.USD","LU2539964713.USD","LU1153584641.USD","LU0432979614.USD","LU2355687059.USD","IE0034235188.USD","LU1291159041.SGD","LU0128525689.USD","BK5011","LU0823416689.USD","LU0211327993.USD","LU0211328371.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653741450","title":"AstraZeneca announces Etcamah with CDK4/6 inhibitor approved in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2653741450","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653741450?lang=en_us&edition=fundamental","pubTime":"2026-07-23 18:46","pubTimestamp":1784803589,"startTime":"0","endTime":"0","summary":"AstraZeneca’s (AZN) Etcamah in combination with a cyclin-dependent kinase, CDK, 4/6 inhibitor has been approved in the European Union, EU, for the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-etcamah-with-cdk4-6-inhibitor-approved-in-eu-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-etcamah-with-cdk4-6-inhibitor-approved-in-eu-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443382.USD","EPV","LU0708994859.HKD","LU1829250122.USD","LU2236285917.USD","LU2468319806.SGD","LU0058720904.USD","AZN","LU0889565916.HKD","LU0128525929.USD","BK4588","BK4156","LU0310800379.SGD","LU2237443549.SGD","AZNH","LU0289739699.SGD","LU0109394709.USD","LU2237443465.HKD","LU1267930573.SGD","BK4568","LU0320765992.SGD","IE00B3T34201.USD","LU2089984988.USD","BK4007","LU2417539215.USD","LU2237443622.USD","LU2237443978.SGD","LU0432979614.USD","LU2462157665.USD","BK4585","LU0029864427.USD","LU2456880835.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653710072","title":"Astrazeneca's Etcamah combination for ESR1-mutated advanced breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653710072","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653710072?lang=en_us&edition=fundamental","pubTime":"2026-07-23 16:50","pubTimestamp":1784796602,"startTime":"0","endTime":"0","summary":"AstraZeneca  said Thursday the European Commission approved its experimental drug, Etcamah, in combination with a CDK4/6 inhibitor, for adults with a type of breast cancer harboring an ESR1 mutation that emerges during first-line endocrine therapy, after the Phase 3 SERENA-6 trial met its primary endpoint.The company said the trial met its primary goal by reducing the risk of disease progression or death by 56% compared with an aromatase inhibitor plus a CDK4/6 inhibitor.Patients receiving the Etcamah combination lived a median of 16 months without their disease worsening, compared with 9.2 months for patients who remained on the comparator regimen, the company said.AstraZeneca said the trial also showed patients lived longer before their disease worsened a second time, while overall survival data remain immature.The company said it will continue evaluating overall survival in the ongoing SERENA-6 trial.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AZN","AZNH","LU0289739699.SGD","LU2462157665.USD","LU2468319806.SGD","LU0029864427.USD","LU0320765992.SGD","LU2456880835.USD","LU0109394709.USD","LU2417539215.USD","LU2237443549.SGD","LU0708994859.HKD","BK4585","LU2236285917.USD","BK4588","LU0058720904.USD","LU0432979614.USD","BK4568","LU2237443622.USD","IE00B3T34201.USD","LU2237443465.HKD","LU0128525929.USD","LU0310800379.SGD","LU2237443978.SGD","LU2089984988.USD","LU0889565916.HKD","LU1829250122.USD","LU2237443382.USD","LU2237443895.HKD","LU1267930573.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189687158","title":"European Union Grants Approval to AstraZeneca's New Breast Cancer Medication","url":"https://stock-news.laohu8.com/highlight/detail?id=1189687158","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189687158?lang=en_us&edition=fundamental","pubTime":"2026-07-23 15:37","pubTimestamp":1784792270,"startTime":"0","endTime":"0","summary":"The European Union has approved the combination therapy of AstraZeneca's drug Etcamah (camizestrant) with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib).This approval is for treating...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","BK4585","LU0029864427.USD","AZNH","IE00B3T34201.USD","LU2237443622.USD","LU0128525929.USD","LU2456880835.USD","LU0058720904.USD","AZN","LU2237443382.USD","LU2417539215.USD","LU0889565916.HKD","LU2237443978.SGD","FSXEmain","LU0432979614.USD","LU1829250122.USD","LU2237443465.HKD","LU2089984988.USD","LU2462157665.USD","LU2237443549.SGD","BK4588","LU1267930573.SGD","LU0289739699.SGD","LU0109394709.USD","IPOS","LU2236285917.USD","LU2237443895.HKD","BK4007","FESXmain","BK4568","LU0708994859.HKD","LU0310800379.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653120761","title":"Astrazeneca PLC Stock Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2653120761","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653120761?lang=en_us&edition=fundamental","pubTime":"2026-07-23 00:00","pubTimestamp":1784736000,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of AstraZeneca PLC advanced 1.9% to SEK1,648.50 Wednesday on what proved to be an overall mediocre trading session for the stock market, with the OMX Nordic 40 Index holding steady at 2,682.26.This was the stock's second consecutive day of gains.The company closed SEK277.00 below its 52-week high of SEK1,925.50, which the company achieved on April 10, 2026.Trading volume was 309,727, compared to the 50-day average trading volume of 320,129.Data source: Dow Jones Market Data, FactSet Dow Jones NewswiresJuly 22, 2026 12:00 ET Copyright  2026 Dow Jones & Company, Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930573.SGD","LU2089984988.USD","LU2237443895.HKD","BK4568","LU0289739699.SGD","BK4588","LU2468319806.SGD","LU0889565916.HKD","LU2462157665.USD","BK4007","LU0432979614.USD","LU2237443978.SGD","LU2237443622.USD","LU0128525929.USD","LU2417539215.USD","LU2456880835.USD","LU0109394709.USD","IE00B3T34201.USD","LU0029864427.USD","LU2237443465.HKD","LU0708994859.HKD","LU0058720904.USD","LU0320765992.SGD","LU0310800379.SGD","BK4585","LU2237443382.USD","AZN","LU1829250122.USD","LU2236285917.USD","LU2237443549.SGD","AZNH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653976865","title":"What Bundibugyo Ebola Vaccines and Treatments are Under Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2653976865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653976865?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:50","pubTimestamp":1784724647,"startTime":"0","endTime":"0","summary":"FACTBOX-What Bundibugyo Ebola vaccines and treatments are under developmentJuly 22 (Reuters)-Global health authorities are racing to identify medical options to help contain an Ebola outbreak in easte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nL4N43O0V6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","LU0114720955.EUR","LU2125154935.USD","MEDI","LU2433249047.HKD","LU1674673691.USD","LU2237443978.SGD","WDNA","LU0320765489.SGD","OSUR","LU2237438978.USD","LU1674673428.USD","LU0238689110.USD","LU2417539215.USD","TBXU","LU1066053197.SGD","LU1066051498.USD","LU1201861249.SGD","LU2106854487.HKD","PAWZ","AZNH","BMED","LU0823434583.USD","LU1066051225.USD","IBB","BBH","IE00B19Z3581.USD","LU0868494617.USD","LU1023059063.AUD","LU0234572021.USD","LU2087621335.USD","ROG","LU0122379950.USD","IE0002270589.USD","LU0985320562.USD","LU1861219969.SGD","LU0265550359.USD","IE00BBT3K403.USD","BK4516","LU1066051811.HKD","LU2362541273.HKD","LU1035773651.USD","LU0006306889.USD","SGXZ57979304.SGD","BK4578","BK4534","LU1934455277.USD","LU2125154778.USD","LU2125909593.SGD","LU1093756325.SGD","BK0239","LU2089984988.USD","SG9999015952.SGD","IE00B1BXHZ80.USD","IE00B7SZLL34.SGD","LU1699723380.USD","IBBQ","BK4583","FTXH","IE00B2B36J28.USD","SG9999014567.USD","LU0029864427.USD","LU0128525929.USD","BK4532","BK4559","LU2468319806.SGD","LU2361045086.USD","688317","IE00B3T34201.USD","LU2361044865.SGD","LU0130102774.USD","LU0320765992.SGD","IE00BSNM7G36.USD","BK4585","LU0098860793.USD","IE00BLSP4452.SGD","LU0965509283.SGD","SG9999015986.USD","IE0002141913.USD","BK4198","LU0689626769.HKD","BK4550","LU0861579265.USD","GDOC","LU0070302665.USD","LU1585245621.USD","MRNA","LU0310800379.SGD","IDNA","LU0889565916.HKD","LU2491049909.HKD","SG9999015945.SGD","LU0823416689.USD","LU1989772840.SGD","LU2361044949.HKD","LU2125909247.SGD","BK4551","TMED","BK4566","FHLC","LU0208291251.USD","PPH","BK4533","LU1974910355.USD","LU2362540622.SGD","LU2023250504.SGD","LU2462157665.USD","LU0980610538.SGD","LU0130517989.USD","SG9999015341.SGD","XLV","LU2357627491.SGD","MRNY","LU1917777945.USD","LU1093756168.USD","LU2362541513.USD","LU2237443465.HKD","IE00B19Z3B42.SGD","LU0203347892.USD","LU1829250122.USD","LU2237443895.HKD","LU0942090050.USD","VHT","LU0266013472.USD","LU0124676726.USD","MRK","LU2236285917.USD","BIB","JDOC","LU2023250843.SGD","MRNX","LU0477156953.USD","IE00BFTCPJ56.SGD","IE00BKVL7J92.USD","SG9999013999.USD","LU1861214812.USD","LGHT","LU2456880835.USD","LU2237443382.USD","LU0648001328.SGD","REGN","LU1778281490.HKD","LU0109394709.USD","BK4139","LU0432979614.USD","BK4007","IXJ","SG9999015978.USD","BK4588","SG9999014559.SGD","LU2237443622.USD","SG9999015358.SGD","LU1162221912.USD","LU1989772923.USD","GNOM","LU2461242641.AUD","SG9999014542.SGD","IE00BJT1NW94.SGD","LU1929549753.HKD","LU0203345920.USD","LU1989771016.USD","LU0234570918.USD","LU0868494708.USD","LU2324357040.USD","LU0289739699.SGD","LU1267930573.SGD","LU1934455194.USD","LU0965509101.SGD","LU2360032135.SGD","SG9999001176.USD","BK4548","SG9999001440.SGD","BK4501","LU1291159041.SGD","LU1923622614.USD","LU1934455863.HKD","LU0708994859.HKD","LU1116320901.HKD","IE00B4R5TH58.HKD","IE00BN8TJ469.HKD","LU1037948541.HKD","IYH","LU1571399168.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU0859254822.USD","LU1983299246.USD","HRTS","LU1037948897.HKD","RXL","LU2112291526.USD","LU2491050154.USD","LU0058720904.USD","SG9999001176.SGD","IE00BLSP4239.USD","LU2237443549.SGD","IHE","BK4148","IE000M9KFDE8.USD","GILD","LU0965508806.USD","AZN","LU0053666078.USD","LU0211331839.USD","LU0320765646.SGD","TRUH","BK4568","LU1430594728.SGD","LU2360107325.USD","IE00BZ1G4Q59.USD","LU0265550946.USD","LU1839511570.USD","SG9999014575.USD","LU1941712264.USD","IE0009355771.USD","LU0106261372.USD","LU0965509010.AUD","LU1057294990.SGD","LU1069347547.HKD","LU2491050071.SGD","SG9999002232.USD","LU0823434740.USD","LU1941712348.USD","LU1116320737.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}